prikaz prve stranice dokumenta Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
  Download
PDF 513.33 KB
Scientific paper - Original scientific paper
Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
Acta Neurobiol Exp, 72 (2012), 3; 264-271. urn:nbn:hr:184:933151
Malnar, Martina; Kosiček, Marko; Bene, Raphael; Petek Tarnik, Iva; Pavelin, Sanda; Babić, Ivana; Brajenović-Milić, Bojana; Hećimovic, Hrvoje; Titlić, Marina; Trkanjec, Zlatko; Demarin, Vida; Hećimović, Silva

Cite this document

Malnar, M., Kosiček, M., Bene, R., Petek Tarnik, I., Pavelin, S., Babić, I. ... Hećimović, S. (2012). Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. Acta Neurobiol Exp, 72. (3), 264-271. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:933151

Malnar, Martina, et al. "Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting." Acta Neurobiol Exp, vol. 72, no. 3, 2012, pp. 264-271. https://urn.nsk.hr/urn:nbn:hr:184:933151

Malnar, Martina, Marko Kosiček, Raphael Bene, Iva Petek Tarnik, Sanda Pavelin, Ivana Babić, Bojana Brajenović Milić, et al. "Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting." Acta Neurobiol Exp 72, no. 3 (2012): 264-271. https://urn.nsk.hr/urn:nbn:hr:184:933151

Malnar, M., et al. (2012) 'Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting', Acta Neurobiol Exp, 72(3), pp. 264-271. Available at: https://urn.nsk.hr/urn:nbn:hr:184:933151 (Accessed 10 July 2024)

Malnar M, Kosiček M, Bene R, Petek Tarnik I, Pavelin S, Babić I, and sur.. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. Acta Neurobiol Exp [Internet]. 2012 [cited 2024 July 10];72(3):264-271. Available at: https://urn.nsk.hr/urn:nbn:hr:184:933151

M. Malnar, et al., "Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting", Acta Neurobiol Exp, vol. 72, no. 3, pp. 264-271, 2012. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:933151. [Accessed: 10 July 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
AuthorMartina Malnar
AuthorMarko Kosiček
AuthorRaphael Bene
AuthorIva Petek Tarnik
AuthorSanda Pavelin
AuthorIvana Babić
AuthorBojana Brajenović-Milić
AuthorHrvoje Hećimovic
AuthorMarina Titlić
AuthorZlatko Trkanjec
AuthorVida Demarin
AuthorSilva Hećimović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Low levels of amyloid-β42 (Aβ42) and high total-tau (t-tau) or phosphorylated-tau (p181-tau) levels in cerebrospinal fluid (CSF) were shown to be characteristic for Alzheimer’s disease (AD) patients and for mildly cognitively impaired (MCI) or non-demented individuals who will progress to AD. The goal of this study was to evaluate the benefit of CSF biomarker testing in a setting with no specialized dementia centers, in order to improve the accuracy of AD diagnosis and to identify individuals with incipient AD. Using ELISA assay we analyzed CSF Aβ42, t-tau and p181-tau levels among clinically diagnosed non-demented individuals, AD patients and individuals with uncertain dementia (n=36). CSF cut-off values of low Aβ42 (≤530 pg/mL) and high t-tau (≥350 pg/mL) or p181-tau (≥52 pg/mL) were used to identify individuals with AD/ MCI-CSF profile, regardless of clinical diagnosis. APOE genotyping was performed using PCR-RFLP method. In accord with previous studies we detected significantly decreased levels of CSF Aβ42 and increased tau and p181-tau levels in clinically diagnosed AD group vs. non-demented controls. CSF profiling identified individuals with a typical AD/MCI-CSF pattern in clinically referred non-demented group (9%) and among patients with uncertain dementia (41.7%). APOE ε4-allele was associated with the CSF biomarker changes typical for AD. This study shows that in a non-specialized setting CSF biomarker testing may be used as a screening tool for improving the accuracy of AD diagnosis and for predicting individuals with incipient Alzheimer’s disease who need to receive further clinical follow-up.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa Neurobiol Exp
Numberingvol. 72, no. 3, pp. 264-271
e-ISSN1689-0035
URN:NBNurn:nbn:hr:184:933151
Publication2012
Document URLhttp://www.ane.pl/pdf/7224.pdf
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-06-14 09:33:19